Vir Biotechnology Inc
$ 9.49
27.73%
24 Feb - close price
- Market Cap 1,033,699,000 USD
- Current Price $ 9.49
- High / Low $ 10.29 / 8.95
- Stock P/E N/A
- Book Value 5.73
- EPS -3.62
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.49 %
- 52 Week High 9.84
- 52 Week Low 4.16
About
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
Analyst Target Price
$16.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-05 | 2025-07-30 | 2025-04-30 | 2025-02-20 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.31 | -1.17 | -0.8 | -0.88 | -0.76 | -1.56 | -1.02 | -0.48 | -0.86 | -1.22 | -1.45 | -1.06 |
| Estimated EPS | -0.5395 | -0.84 | -0.7754 | -0.8433 | -0.89 | -1.05 | -0.9 | -1.05 | -1.01 | -1.21 | -1.2 | -0.87 |
| Surprise | 0.2295 | -0.33 | -0.0246 | -0.0367 | 0.13 | -0.51 | -0.12 | 0.57 | 0.15 | -0.01 | -0.25 | -0.19 |
| Surprise Percentage | 42.5394% | -39.2857% | -3.1726% | -4.352% | 14.6067% | -48.5714% | -13.3333% | 54.2857% | 14.8515% | -0.8264% | -20.8333% | -21.8391% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.6513 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VIR
2026-02-24 02:10:06
Vir Biotechnology announced positive updated Phase 1 results for VIR-5500, a PSMA-targeting, PRO-XTEN® dual-masked T-cell engager, in patients with metastatic castration-resistant prostate cancer. The study showed a favorable safety profile with no dose-limiting toxicities and significant anti-tumor activity, including PSA50 and PSA90 declines, and objective responses in highly pre-treated patients. The company plans to advance to dose-expansion cohorts and initiate a registrational trial in 2027, highlighting VIR-5500's potential for improving outcomes in prostate cancer.
2026-02-24 00:22:06
Vir Biotechnology and Astellas US LLC have formed a major global collaboration to co-develop and commercialize VIR-5500, a T-cell engager for advanced prostate cancer. The deal provides Vir with $335 million upfront, potential milestones up to $1.37 billion, and shared development costs and U.S. profits, while Astellas gains exclusive commercialization rights outside the U.S. Astellas is also investing $75 million in Vir, strengthening both companies' positions in oncology.
2026-02-23 22:22:06
Vir Biotechnology, Inc. has announced positive progress in its dose expansion cohorts for research and development projects. The company aims to officially launch key registrational clinical trials in 2027, marking a significant step towards regulatory approvals and potential commercialization of its core therapies.
2026-02-23 22:22:06
Astellas Pharma Inc. and Vir Biotechnology, Inc. have announced a global strategic collaboration to advance VIR-5500, an investigational PRO-XTEN® dual-masked CD3 T-cell engager targeting PSMA for prostate cancer. This collaboration aims to accelerate development, with Astellas leading commercialization in the U.S. and globally outside the U.S., while Vir Biotechnology receives $335 million in upfront and near-term payments, with potential for an additional $1.37 billion in milestones. The partnership leverages Astellas' expertise in oncology and Vir Biotechnology's PRO-XTEN® platform to address unmet needs in metastatic castration-resistant prostate cancer.
2026-02-23 22:22:06
Vir Biotechnology Inc. (VIR) reported its Q4 earnings, surpassing analyst estimates by $0.23 with an EPS of ($0.31). The company also significantly exceeded revenue consensus, bringing in $64.07 million against an expected $1.42 million. This positive financial performance indicates a strong quarter for the biotechnology firm.
2026-02-23 22:22:06
Vir Biotechnology, Inc. has released its annual 10-K report, detailing financial highlights including total revenues of $68.6 million and a net loss of $(438.0) million, an improvement from the previous year. The report outlines the company's focus on developing therapies for infectious diseases and cancer, its strategic collaborations, and future plans for clinical trials. It also addresses significant challenges such as the need for additional funding, regulatory obstacles, and market competition.
